01:24 PM EDT, 05/19/2025 (MT Newswires) -- Stryker (SYK) said Monday its OptaBlate basivertebral nerve ablation system received 510(k) clearance from the US Food and Drug Administration.

OptaBlate is used in a minimally invasive procedure to provide relief from vertebrogenic low back pain, the company said.

Stryker said the system, which expands its advanced pain therapy portfolio, combines its competencies in radiofrequency ablation and vertebral access.

Price: 393.34, Change: -0.88, Percent Change: -0.22